Skip to content
Ep. 172 - AACR Insights episode artwork

Apr 20, 2023 22 min

Ep. 172 - AACR Insights

from BioCentury This Week Hosted by BioCentury

BioCentury’s analysis of AACR 2023 abstracts found new targets light on immuno-oncology, said Executive Director Lauren Martz on a special edition of the BioCentury This Week podcast. Martz and colleagues debated whether the findings suggest immuno-oncology is losing its luster, and assessed abstracts on next-generation PRMT5 inhibitors and first-in-human studies, as well as the latest data from Merck & Co. and Moderna on their neoantigen vaccine in melanoma. Reach us by sending a text

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Ep. 172 - AACR Insights

0:00 22:30

Chapters

  1. 0:28 New Molecular Targets
  2. 4:43 PRMT5 & KRAS
  3. 9:42 First in Human
  4. 12:58 Merck, Moderna Readout

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of BioCentury This Week?

This episode is 22 minutes long.

When was this BioCentury This Week episode published?

This episode was published on April 20, 2023.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.